TREATMENT OF CONDYLOMA ACUMINATUM WITH 3 DIFFERENT INTERFERON-ALPHA PREPARATIONS ADMINISTERED PARENTERALLY - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

被引：39

作者：

REICHMAN, RC

OAKES, D

BONNEZ, W

BROWN, D

MATTISON, HR

BAILEYFARCHIONE, A

STOLER, MH

DEMETER, LM

TYRING, SK

MILLER, L

WHITLEY, R

CARVETH, H

WEIDNER, M

KRUEGER, G

CHOI, A

机构：

[1] UNIV ROCHESTER,SCH MED,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642

[2] UNIV ROCHESTER,SCH MED,DEPT PATHOL,ROCHESTER,NY 14642

[3] UNIV ROCHESTER,SCH MED,DIV BIOSTAT,ROCHESTER,NY 14642

[4] UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35233

[5] UNIV ALABAMA,DEPT DERMATOL,BIRMINGHAM,AL 35233

[6] UNIV UTAH,DEPT MED,DIV DERMATOL,SALT LAKE CITY,UT 84112

来源：

JOURNAL OF INFECTIOUS DISEASES | 1990年 / 162卷 / 06期

关键词：

D O I：

10.1093/infdis/162.6.1270

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

One hundred seventy-eight patients were enrolled in a placebo-controlled trial to evaluate three interferon-α preparations administered parenterally for the treatment of condyloma acuminatum. When all interferon groups were combined and compared with placebo, interferon recipients had greater rates ofcomplete, 75%, 50%, and 25% lesion resolution than did placebo recipients (P =.21, P =.14, P =.02, and P =.02, respectively). Rates of lesion resolution were higher among women than among men, and women were more likely than men to respond to interferon. Virologic measurements in paired lesion biopsies did not correlate with interferon treatment or disease outcome. Although interferon toxicity was observed frequently, no participant withdrew from the study because of side effects, and dosage alterations were not required. Parenterally administered interferon-α is more effective than placebo in treating condyloma acuminatum, although rates of complete response are low. Different regimens, including combination therapy, should be evaluated for treatment of this common sexually transmitted disease. © 1990, by The University of Chicago.

引用

页码：1270 / 1276

页数：7

共 22 条

[1]

Koutsky L.A., Galloway D.A., Holmes K.K., Epidemiology of genital human papillomavirus infection, Epidemiol Rev, 10, pp. 122-163, (1988)

[2]

Kashima H.K., Shah K., Recurrent respiratory papillomatosis, Obstet Gynecol Clin North Am, 14, pp. 581-588, (1987)

[3]

Zur Hausen H., Genital papillomavirus infections, Prog Med Virol, 32, pp. 15-21, (1985)

[4]

Gissmann L., Durst M., Oltersdorf T., Von Knebel Doeberitz M., Human papilloma viruses and cervical cancer, 5, pp. 275-280, (1987)

[5]

Eron L.J., Judson F., Tucker S., Prawer S., Mills J., Murphy K., Hickey M., Rogers M., Flannigan S., Hein N., Katz H.I., Goldman S., Gottlieb A., Adams K., Burton P., Tanner D., Taylor E., Peets E., Interferon therapy for condylomata acuminata, N Engl J Med, 315, pp. 1059-1064, (1986)

[6]

Friedman-Kien A., Eron L.J., Conant M., Growdan W., Babiak H., Brad-street P.W., Fedorczyk D., Trout R., Plasse T.F., Natural interferon-α for the treatment of condylomata acuminata, JAMA, 259, pp. 533-538, (1988)

[7]

Vance J.C., Bart B.J., Hansen R.C., Reichman R.C., McEwen C., Hatch K.D., Berman B., Tanner D., Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris, Arch Dermatol, 122, pp. 272-277, (1986)

[8]

Reichman R.C., Oakes D., Bonnez W., Greisberger C., Tyring S., Miller L., Whitley R., Carveth H., Weidner M., Krueger G., Yorkey L., Roberts N.J., Dolin R., Treatment of condyloma acuminatum with three different interferons administered intralesionally, Ann Intern Med, 108, pp. 675-679, (1988)

[9]

Schonfeld A., Nitke S., Schattner A., Wallach D., Crespi M., Hahn T., Hahn H., Yarden O., Shoham J., Doerner T., Revel M., Intramuscular human interferon-β injections in treatment of condylomata acuminata, Lancet, 1, pp. 1038-1042, (1984)

[10]

Kirby P.K., Kiviat N., Beckman A., Wells D., Sherwin S., Corey L., Tolerance and efficacy of recombinant human interferon-γ in the treatment of refractory genital warts, Am J Med, 85, pp. 183-188, (1988)

← 1 2 3 →